Client News
Roquefort Therapeutics PLC: Acquisition Completion, Admission & Voting RightsHome / Client News / Roquefort Therapeutics PLC: Acquisition Completion, Admission & Voting Rights
Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, is pleased to announce the completion of its acquisition of the entire issued share capital of Oncogeni Limited (“Oncogeni”) for an aggregate consideration of £5,500,000 satisfied by the issue of 50,000,000 new ordinary shares in the Company (“Consideration Shares”) to the shareholders of Oncogeni (the “Acquisition”).
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
CLIENT AREA
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.